ALISO VIEJO, Calif., Oct. 12, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that pseudobulbar affect (PBA) prevalence data from stroke survivors will be highlighted at the 88th Annual Meeting of the American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in Atlanta, GA.
Following are details about the data presentation at ACRM/ASNR Progress in Rehabilitation Research:
Title: Pseudobulbar Affect in Stroke: A National Stroke Association Survey
Program Number: 0025
Presentation Date/Time: Thursday, October 13, 2011 5:00-7:00 p.m. EST & Friday October 14, 2011 4:30-6:45 p.m. EST
About PBA
Patients suffering from existing neurological disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of crying and/or laughing. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition-such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit www.PBAinfo.org.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.
AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners
©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.
SOURCE Avanir Pharmaceuticals, Inc.